Young investigator challenge: Cadherin‐17 and SATB2 in cytology specimens: Do these new immunostains help in differentiating metastatic colorectal adenocarcinoma from adenocarcinomas of other origins?

Abstract

BACKGROUND: Cadherin-17 (intestinal peptide-associated transporter) and SATB2 (SATB homeobox 2) immunoexpression has recently been described in surgical pathology to have value in establishing the colorectal origin of metastatic adenocarcinoma. However, to the authors' knowledge, the role of these markers in metastatic colorectal adenocarcinoma (MCA) in cytology has not been addressed to date. In the current study, the authors evaluated the contribution of cadherin-17 and SATB2 to the diagnosis of MCA in cytology specimens and compared these two novel markers with the

SATB2 is a supplementary immunohistochemical marker to CDX2 in the diagnosis of colorectal carcinoma metastasis in an unknown primary

“…High sensitivity makes CDX2 a useful marker in the daily practice for determining primary, but its specificity can be of concern. SATB2 as a more recently described marker of colorectal origin, also has a high level of sensitivity ranging from 80% to 97% as reported in some studies (7,12). On the contrary, our study showed increased specificity of SATB2 compared with CDX2 but not increased sensitivity.…”

SATB2 targeted by methylated miR‐34c‐5p suppresses proliferation and metastasis attenuating the epithelial‐mesenchymal transition in colorectal cancer

“…In actuality, both SATB1 and SATB2 have been found to be involved in the pathogenesis of CRC, with SATB2 being reported to be lower in CRC tissues compared with normal controls . Nonetheless, considering that SATB2 expression is selectively expressed in the lower gastrointestinal tract mucosa, SATB2 was more commonly used alone or together with other markers than SATB1 for differential pathology diagnosis of CRC from other tumours with morphological similarity, we have, therefore, picked up SATB2, as opposed to SATB1, in our present study, in an attempt to confirm the previous finding in our own cases that SATB2 has been reported to be significantly down‐regulated in CRC. As expected, the observational association we made between the clinicopathological significance and status of SATB2 in CRC was totally in agreement with previous reports that down‐regulated expression of SATB2 was closely linked with metastasis, whatever distant or lymph node, and poor overall survival in CRC.…”

SATB2 as an Immunohistochemical Marker for Colorectal Adenocarcinoma: A Concise Review of Benefits and Pitfalls

“…23,24 The utility of SATB2 as a marker for metastatic colorectal adenocarcinoma in 111 cytology specimens was assessed as compared with a standard panel of CK7, CK20, and CDX2. 25 Use of SATB2 as a solitary marker had a sensitivity of 60% and a specificity of 91%, whereas the standard panel had a sensitivity of 79% and a specificity of 100%. When SATB2 was added to the standard panel, there was no significant difference in predictive value.…”

“…The conclusion was that SATB2 did not add any additional value to the standard panel for diagnosing colorectal metastases in cytology specimens. 25…”